Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain

被引:216
作者
Kreuter, Jorg
Hekmatara, Telli
Dreis, Sebastian
Vogel, Tikva
Gelperina, Svetlana
Langer, Klaus
机构
[1] Univ Frankfurt, Inst Pharmazeut Technol, Biozentrum, D-60438 Frankfurt, Germany
[2] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA
[3] NCI, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA
[4] Res Ctr Mol Diagnost & Therapy, Moscow, Russia
关键词
nanoparticles; apolipoprotein A-I; apolipoprotein B-100; apolipoprotein E3; human serum albumin (HSA); brain uptake; drug targeting;
D O I
10.1016/j.jconrel.2006.12.012
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Apolipoprotein E3, A-I as well as B-100 were covalently attached to human serum albumin nanoparticles via the NES-PEG-Mal 3400 linker. Loperamide as a model drug was bound to these nanoparticles, and the antinociceptive reaction of these preparations was recorded after intravenous injection in mice by the tail-flick test. After 15 min, all three nanoparticle preparations with the coupled apolipoproteins E3, A-I, and B-100 yielded considerable antinociceptive effects, which lasted over 1 h. The maximally possible effects [MPE] of these preparations amounted to 95%, 65%, and 50%, respectively, and were statistically different from the controls (p < 0.02), whereas the loperamide solution achieved no effect. This result demonstrates that more than one mechanism is involved in the interaction of nanoparticles with the brain endothelial cells and the resulting delivery of drugs to the central nervous system. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:54 / 58
页数:5
相关论文
共 28 条
[21]   ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in Vitro blood-brain barrier constituted of porcine brain capillary endothelial cells [J].
Panzenboeck, U ;
Balazs, Z ;
Sovic, A ;
Hrzenjak, A ;
Levak-Frank, S ;
Wintersperger, A ;
Malle, E ;
Sattler, W .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (45) :42781-42789
[22]  
PETRI B, IN PRESS J CONTROLLE
[23]   Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of iv dalargin injections [J].
Schroder, U ;
Sabel, BA .
BRAIN RESEARCH, 1996, 710 (1-2) :121-124
[24]   Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles [J].
Steiniger, SCJ ;
Kreuter, J ;
Khalansky, AS ;
Skidan, IN ;
Bobruskin, AI ;
Smirnova, ZS ;
Severin, SE ;
Uhl, R ;
Kock, M ;
Geiger, KD ;
Gelperina, SE .
INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (05) :759-767
[25]   VISUALIZATION OF THE BINDING, ENDOCYTOSIS, AND TRANSCYTOSIS OF LOW-DENSITY LIPOPROTEIN IN THE ARTERIAL ENDOTHELIUM INSITU [J].
VASILE, E ;
SIMIONESCU, M ;
SIMIONESCU, N .
JOURNAL OF CELL BIOLOGY, 1983, 96 (06) :1677-1689
[26]   HUMAN APOLIPOPROTEIN-E EXPRESSION IN ESCHERICHIA-COLI - STRUCTURAL AND FUNCTIONAL IDENTITY OF THE BACTERIALLY PRODUCED PROTEIN WITH PLASMA APOLIPOPROTEIN-E [J].
VOGEL, T ;
WEISGRABER, KH ;
ZEEVI, MI ;
BENARTZI, H ;
LEVANON, AZ ;
RALL, SC ;
INNERARITY, TL ;
HUI, DY ;
TAYLOR, JM ;
KANNER, D ;
YAVIN, Z ;
AMIT, B ;
AVIV, H ;
GORECKI, M ;
MAHLEY, RW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (24) :8696-8700
[27]   Desolvation process and surface characterisation of protein nanoparticles [J].
Weber, C ;
Coester, C ;
Kreuter, J ;
Langer, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 194 (01) :91-102
[28]   Desolvation process and surface characteristics of HSA-nanoparticles [J].
Weber, C ;
Kreuter, J ;
Langer, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 196 (02) :197-200